Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia (QOLIBRI)

Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice

The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).

Study Overview

• Status: Recruiting
• Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
• Intervention / Treatment: Behavioral: Individual Physical Activity Intervention (IPAI); Drug: Ibrutinib

• Study Type: Observational
• Enrollment (Estimated): 256

Contacts and Locations

• Study Contact: Name: Study Contact; Phone Number: 844-434-4210; Email: Participate-In-This-Study@its.jnj.com

Study Locations

• France
  • Toulouse, France, 31100
    • Recruiting
    • Institut Universitaire du Cancer Toulouse Oncopole

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study population will include participants aged at least 18 years of age with chronic lymphocytic leukemia (CLL).

Description

Inclusion Criteria:

• Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)
• Participants agreed to follow the individual physical activity intervention (IPAI)
• Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet
• Participants with Internet access at home and email address
• Participants agreed to wear a connected watch 24 hours a day for all the duration of the study

Exclusion Criteria:

• Pregnant participants or planning to become pregnant while enrolled in this study
• Participants with inability or deemed unsafe to practice physical activity
• Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit
• Participants who are currently involved in an interventional study
• Participants with probable difficulties in using the digital tool autonomously

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1: Individual Physical Activity Intervention; Participants with chronic lymphocytic leukemia (CLL) will be invited to perform physical activity according to a predefined intervention program. This program includes walking and weekly remote adapted physical activity sessions (2 sessions per week, the duration and difficulty of which will be adapted by the adapted physical activity [APA] trainer according to the Participant's abilities).	Behavioral: Individual Physical Activity Intervention (IPAI); No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.; Drug: Ibrutinib; No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
Group 2: Standard of Care; Participants with CLL will continue physical activity according to their lifestyle and the recommendations of the medical team.	Drug: Ibrutinib; No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Health-related Quality of Life (HRQoL) by Using Functional Assessment of Cancer Therapy General (FACT-G) Total Score at Month 4.5	The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL.	Baseline and Month 4.5

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in HRQoL by Using Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) Total Score at Month 4.5, Month 6.5 and Month 12	The FACT-Leu questionnaire consists of 44 questions grouped into 5 dimensions: PWB (7 items), SWB (7 items), EWB (6 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-Leu score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL.	Baseline, Month 4.5, Month 6.5, and Month 12
Change from Month 4.5 in HRQoL by Using FACT-Leu Total Score at Month 6.5	The FACT-Leu questionnaire consists of 44 questions grouped into 5 dimensions: PWB (7 items), SWB (7 items), EWB (6 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-Leu score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL.	Month 4.5 and Month 6.5
Change from Month 6.5 in HRQoL by Using FACT-Leu Total Score at Month 12	The FACT-Leu questionnaire consists of 44 questions grouped into 5 dimensions: PWB (7 items), SWB (7 items), EWB (6 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-Leu score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL.	Month 6.5 and Month 12
Change from Baseline in HRQoL by Using Trial Outcome Index (TOI) Total Score at Month 4.5, Month 6.5, and Month 12	The TOI questionnaire consists of 31 questions grouped into 5 dimensions: PWB (7 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total TOI score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL.	Baseline, Month 4.5, Month 6.5, and Month 12
Change from Month 4.5 in HRQoL by Using Trial Outcome Index (TOI) Total Score at Month 6.5	The TOI questionnaire consists of 31 questions grouped into 5 dimensions: PWB (7 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total TOI score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL.	Month 4.5 and Month 6.5
Change from Month 6.5 in HRQoL by Using Trial Outcome Index (TOI) Total Score at Month 12	The TOI questionnaire consists of 31 questions grouped into 5 dimensions: PWB (7 items), FWB (7 items) and additional concerns (LEUS; 17 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total TOI score is the summation of 5 subscale scores and ranges from 0-176. Higher scores for the scales and subscales indicate better HRQoL.	Month 6.5 and Month 12
Change from Baseline in HRQoL by Using FACT-G Scale at Month 6.5 and Month 12	The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL.	Baseline, Month 6.5, and Month 12
Change from Month 4.5 in HRQoL by Using FACT-G Scale at Month 6.5	The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL.	Month 4.5 and Month 6.5
Change from Month 6.5 in HRQoL by Using FACT-G Scale at Month 12	The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL.	Month 6.5 and Month 12
Percentage of Participants Achieving a Greater Than or Equal to (>=) 5-Point Improvement in the FACT-G Total Score at Months 4.5, 6.5, and 12 as Compared to Baseline	The FACT-G consists of 27 questions grouped in 4 dimensions: physical well-being (PWB; 7 items), social/family well-being (SWB; 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). Each item is given a weighted score of 0 to 4 and the score of each dimension are obtained by addition of the weighted scores of each item corresponding to the dimension. Total FACT-G score is the summation of 4 subscale scores and ranges from 0-108. Higher scores for the scales and subscales indicate better HRQoL.	Baseline, Month 4.5, Month 6.5, and Month 12
Change from Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score at Month 4.5, Month 6.5, and Month 12	The FACIT-fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists of 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score is calculated as the sum of the 13 item scores (reserved scores [4 - score]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in the Pittsburgh Sleep Quality Index (PSQI) Total Score and Sub Score at Month 4.5, Month 6.5, and Month 12	PSQI is used to detect sleep disturbance or deficits. It contains 19 self-rated items that are combined to form seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction The PSQI has a scoring key that can be used to calculate a participant's seven sub scores, which range from 0 to 3. The sub scores are added together to produce a "global" score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Total Sleep Time Using Connected Watch	Change from baseline in total sleep time (in hours) using connected watch will be assessed.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Total Sleep Score Using Connected Watch	Change from baseline in total sleep score (time asleep/time in bed) based on duration, regularity, depth and interruption using connected watch will be assessed.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Sleep Stages Using Connected Watch	Change from baseline in sleep stages (deep/light) using connected watch will be assessed.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Hospital Anxiety and Depression (HAD) Score at Month 4.5, Month 6.5, and Month 12	The HAD scale is a 14-items measure that assesses anxiety and depressive disorders. The scale includes seven questions related to anxiety (total A) and seven others to the depressive dimension (total D). Each item is rated from 0 to 3. Two scores are derived from the scale, one related to anxiety and the other related to depression (maximum score for each score = 21). Higher scores indicate increased anxiety or depression.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Physical Fitness as Measured by Six-Minute Walk Test (6MWT) at Month 4.5, Month 6.5, and Month 12	The 6MWT is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. It is easy to administer, better tolerated, and more reflective of activities of daily living than the other walk tests.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Physical Activity as Assessed by Number of Steps per Day Using Connected Watch	Change from baseline in physical activity as assessed by number of steps per day using connected watch will be reported.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Physical Activity as Assessed by the Number of Walking Sessions per Week using Connected Watch	Change from baseline in physical activity as assessed by the number of walking sessions per week using connected watch will be reported.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Physical Activity as Assessed by the Time of Walking Sessions per Week Using Connected Watch	Change from baseline in physical activity as assessed by the time of walking sessions per week using connected watch will be reported.	Baseline, Month 4.5, Month 6.5, and Month 12
Change From Baseline in Physical Activity as Assessed by the Distance of Walking Sessions per Week Using Connected Watch	Change from baseline in physical activity as assessed by the distance of walking sessions per week using connected watch will be reported.	Baseline, Month 4.5, Month 6.5, and Month 12
Percentage of Participants with Treatment-related Adverse Events	Percentage of participants with treatment-related adverse events especially musculoskeletal and cardiovascular treatment-related adverse events will be reported.	Up to 30 months
Time to Treatment Discontinuation (TTD)	TTD is defined as the time between the first day of ibrutinib treatment and the day that ibrutinib is definitely stopped for whatever reason or death.	Months 6 and 12
Reasons for Treatment Discontinuation	Number of participants in each reason for treatment discontinuation will be reported. Reasons for treatment discontinuation are defined as: adverse events, lack of efficacy, patient's convenience, physician's decision, progression, death or other.	Up to Month 12
Percentage of Participants Who Still Wear the Connected Watch	Percentage of participants who still wear the connected watch (adherence) will be assessed.	Months 1, 3, 4.5, 6.5, and 12
Percentage of Participants Retained by the Connected Watch (Start Wearing the Watch)	Percentage of participants retained by the connected watch (start wearing the watch) will be assessed.	Months 1, 3, 4.5, 6.5, and 12
Percentage of Participants Agreed to Participate in the Study Among Eligible participants with Chronic Lymphocytic Leukemia (CLL) Initiation Ibrutinib Treatment	Percentage of participants agreed to participate in the study among eligible participants with CLL initiation ibrutinib treatment will be reported.	During the first 6 months (Feasibility period)
For Group 1: Percentage of Participants Who Still Follow the Individual Physical Activity Intervention (IPAI) Among Those Who Have Started IPAI	Percentage of participants who still follow the IPAI among those who have started IPAI (Adherence) in group 1 will be assessed.	Months 1, 3, 4.5, and 6.5
For Group 1: Percentage of Participants Who Follow the Adapted Physical Activity (APA) Sessions, the Walking Objectives and the APA Appointment as Scheduled With the APA Among Those Who Have Started IPAI	Percentage of participants who follow the adapted physical activity sessions, the walking objectives and the APA appointment as scheduled with the APA among those who have started IPAI (Compliance) in group 1 will be assessed.	Months 1, 3, 4.5, and 4.6
For Group 1: Percentage of Participants Retained by the IPAI (First APA Videoconference Attended) Among Participants Enrolled in the Study	Percentage of participants retained by the IPAI (first APA videoconference attended) among participants enrolled in the study will be assessed.	Months 1 and 3
For Group 1: Percentage of Participants who Completed the Supervised Period Among Participants Enrolled in the Study	Percentage of participants who completed the supervised period among participants enrolled in the study will be assessed.	Month 4.5
For Group 1: Percentage of Participants who Completed the Unsupervised Period Among Participants Enrolled in the Study	Percentage of participants who completed the unsupervised period among participants enrolled in the study will be assessed.	Month 6.5
For Group 1: Participant Satisfaction With the IPAI Measured With the Satisfaction Likert Scale	Participant's' satisfaction will be assessed by Likert scales at Months 4.5 and 6.5 regarding coaching, proposed sessions, program content, program duration, impact on APA practice, overall satisfaction, willingness to continue and recommendation to others. Likert scales will assess participant's' satisfaction at Month 12 regarding impact on APA practice, overall satisfaction, willingness to continue and recommendation to others. Only one question is quantitative with score range from 0 (not at all satisfied) to 10 (totally satisfied) for global satisfaction. Participants are considered satisfied when score is greater than or equal to (>=) 6 and highly-satisfied when score is >=8. All other questions are qualitative and have 5-level Likert scales including: very satisfied, rather satisfied, neither satisfied nor dissatisfied, not really satisfied, not at all satisfied.	Months 4.5, 6.5, and 12

Collaborators and Investigators

• Sponsor: Janssen Cilag S.A.S.
• Investigators: Study Director: Janssen Cilag S.A.S., France Clinical Trial, Janssen Cilag S.A.S.

Study record dates

Study Major Dates

• Study Start (Estimated): May 15, 2024
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026

Study Registration Dates

• First Submitted: March 1, 2024
• First Submitted That Met QC Criteria: March 1, 2024
• First Posted (Actual): March 8, 2024

Study Record Updates

• Last Update Posted (Estimated): May 16, 2024
• Last Update Submitted That Met QC Criteria: May 15, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; Hematologic Diseases; Leukemia, B-Cell; Chronic Disease; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Ibrutinib
• Other Study ID Numbers: 54179060CLL4033 (Other Identifier: Janssen-Cilag France)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No